Bronchiectasis Clinical Landscape Report 2026: Trials, Readouts and White Space

Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.

Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.

Executive view

Bronchiectasis remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 292 matched trial records and 88 indexed result records before the decision-focused sample below was selected.

How PatSnap MCP built this report

The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.

Trial landscape table

The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.

What indexed results say

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study (Phase 3): the indexed record reports Annualized Rate of Pulmonary Exacerbations (PEs) = 1.286 exacerbation per participant-year (95% Confidence Interval, 1.158 - 1.428); Annualized Rate of Pulmonary Exacerbations (PEs) = 1.015 exacerbation per participant-year (95% Confidence Interval, 0.910 - 1.132); Annualized Rate of Pulmonary Exacerbations (PEs): Rate ratio = 0.789(95% CI, 0.680 - 0.916), P-Value = 0.0019; Rate ratio = 0.806(95% CI, 0.694 - 0.936), P-Value = 0.0046.
• A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Evaluating Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 1291583 One Tablet Once Daily Over 12 Weeks Versus Placebo in Adult Patients With Cystic Fibrosis Bronchiectasis (Clairafly™) (Phase 2): the indexed record reports Occurrence of Any Treatment Emergent Adverse Events = 85.7 Percentage of participants; -; -.
• Hypertonic Saline or Carbocisteine in Bronchiectasis (Not Applicable): the indexed record reports Pulmonary exacerbations = 0.9 Event ( 0.7 - 1.09); Pulmonary exacerbations = 0.86 Event ( 0.66 - 1.06); Pulmonary exacerbations = 0.76 Event ( 0.58 - 0.95).

Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.

Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.

Asset and sponsor context

PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including RSS-0343 (Phase 2; DPP-1), Rifampin (Approved; RNAP), Clarithromycin (Approved; 50S subunit). Company & Deal Intelligence records identify sponsor context for Reistone Biopharma Co. Ltd., Tel Aviv Sourasky Medical Center, The First Affiliated Hospital of Nanchang University, Taipei Veterans General Hospital. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.

Where the white space is

1. Clinically meaningful endpoints paired with virologic or microbiologic measures.
2. Evidence in immunocompromised, pediatric, pregnant and older populations.
3. Resistance surveillance and combination strategies for prolonged infection.
4. Coadministration, real-world effectiveness and implementation studies.

Strategic implications

For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.

What to monitor next

Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.

Bottom line

Bronchiectasis has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.